Krilogy Financial LLC Has $2.20 Million Holdings in Exact Sciences Corporation (NASDAQ:EXAS)

Krilogy Financial LLC grew its holdings in shares of Exact Sciences Corporation (NASDAQ:EXAS - Free Report) by 139.6% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 50,863 shares of the medical research company's stock after purchasing an additional 29,636 shares during the period. Krilogy Financial LLC's holdings in Exact Sciences were worth $2,202,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in EXAS. Asset Planning Inc bought a new stake in shares of Exact Sciences in the fourth quarter valued at approximately $40,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Exact Sciences in the 4th quarter valued at $45,000. AlphaQuest LLC lifted its position in shares of Exact Sciences by 22,825.0% during the 4th quarter. AlphaQuest LLC now owns 917 shares of the medical research company's stock valued at $52,000 after acquiring an additional 913 shares during the period. SBI Securities Co. Ltd. acquired a new stake in shares of Exact Sciences during the 4th quarter worth $66,000. Finally, Ostrum Asset Management grew its holdings in shares of Exact Sciences by 28.4% during the 4th quarter. Ostrum Asset Management now owns 2,382 shares of the medical research company's stock worth $134,000 after purchasing an additional 527 shares in the last quarter. 88.82% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on EXAS shares. Mizuho started coverage on shares of Exact Sciences in a research report on Thursday, April 10th. They set an "outperform" rating and a $60.00 price objective for the company. Evercore ISI upped their price target on shares of Exact Sciences from $60.00 to $66.00 and gave the stock an "outperform" rating in a report on Friday, May 2nd. Guggenheim reiterated a "buy" rating and set a $60.00 price target on shares of Exact Sciences in a research report on Friday, April 11th. Barclays lifted their price objective on shares of Exact Sciences from $55.00 to $75.00 and gave the company an "overweight" rating in a research note on Friday, May 2nd. Finally, Robert W. Baird upped their target price on Exact Sciences from $69.00 to $72.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $70.90.

Exact Sciences Trading Down 1.4%

Shares of Exact Sciences stock traded down $0.76 on Tuesday, hitting $52.54. The stock had a trading volume of 2,523,280 shares, compared to its average volume of 2,601,999. The stock has a 50 day moving average of $51.39 and a 200 day moving average of $51.98. The firm has a market capitalization of $9.91 billion, a P/E ratio of -9.54 and a beta of 0.98. Exact Sciences Corporation has a twelve month low of $39.97 and a twelve month high of $72.83. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.38 and a current ratio of 2.73.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.16. The firm had revenue of $706.79 million during the quarter, compared to analysts' expectations of $688.58 million. Exact Sciences had a negative net margin of 36.06% and a negative return on equity of 3.75%. The company's revenue was up 10.9% on a year-over-year basis. During the same period in the prior year, the company posted ($0.60) EPS. Sell-side analysts expect that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Exact Sciences news, Director Katherine S. Zanotti sold 3,207 shares of the company's stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $53.20, for a total value of $170,612.40. Following the sale, the director now owns 72,759 shares in the company, valued at approximately $3,870,778.80. The trade was a 4.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 1.20% of the stock is owned by corporate insiders.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.